<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2413-4341</journal-id>
<journal-title><![CDATA[Revista Paraguaya de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. parag. reumatol.]]></abbrev-journal-title>
<issn>2413-4341</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Paraguaya de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2413-43412022000100011</article-id>
<article-id pub-id-type="doi">10.18004/rpr/2022.08.01.11</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectos adversos relacionados a infusión endovenosa de ciclofosfamida en pacientes de un hospital de referencia]]></article-title>
<article-title xml:lang="en"><![CDATA[Adverse effects related to intravenous infusion of cyclophosphamide in patients in a referral hospital]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lugo]]></surname>
<given-names><![CDATA[María Elvira Miskinich]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Duré]]></surname>
<given-names><![CDATA[César Damián Riveros]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rotela]]></surname>
<given-names><![CDATA[Auda Alice Quintana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[Elvis Javier Ibáñez]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cristaldo]]></surname>
<given-names><![CDATA[José David Cabañas]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[Mónica Martínez Ruiz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Britez]]></surname>
<given-names><![CDATA[Delcy Verónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Méreles]]></surname>
<given-names><![CDATA[Kathia Gisselle Medina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montiel]]></surname>
<given-names><![CDATA[Dora Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Itapuá Facultad de Medicina Postgrado en Medicina Interna]]></institution>
<addr-line><![CDATA[Encarnación ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Nacional de Itauguá Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Itauguá ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>8</volume>
<numero>1</numero>
<fpage>11</fpage>
<lpage>15</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2413-43412022000100011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2413-43412022000100011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2413-43412022000100011&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Introducción: La ciclofosfamida es un fármaco de la familia de agentes alquilantes utilizada como antineoplásico e inmunodepresor. Es un fármaco muy tóxico y tiene muchos efec tos adversos por lo que, dentro de las enfermedades autoinmunes, se reserva a aquellos con afectación severa para inducir la remisión de la enfermedad. Objetivos: Determinar los efectos adversos relacionados a la infusión endovenosa de ciclofosfamida en pacientes del Hospital Nacional, Itauguá, periodo 2020-2021. Métodos: Se realizó estudio prospectivo, observacional, descriptivo. Los datos se obtuvieron de una encuesta realizada a los pacientes al momento del reclutamiento y se extrapolaron a una planilla Excel y analizados mediante el programa estadístico EPI INFO 7. Resultados: La muestra estuvo compuesta de 70 pacientes, con edad media de 38±15 años, 44 (63%) fueron mujeres, 51 (73%) recibió como tratamiento inmunosupresor en enfermedades autoinmunes y 19 (27%) como tratamiento antineoplásico. Las comorbilidades detectadas fueron hipertensión arterial en 37 pacientes (47%), diabetes mellitus en 1 paciente (1%) y asma bronquial en 2 pacientes (3%). Presentaron efectos adversos 51 pacientes (73%), se identificaron 82 eventos adversos, los cuales fueron hiponatremia en 25 (36%), taquicardia en 19 (27%, náuseas en 18 (26%), leucopenia en 15 (20%), y prolongación del QTc en 5 (7%). Conclusión: Predominó el sexo femenino con edad media de 38 años. El efecto adverso más frecuente fue hiponatremia, siendo severa en 3 pacientes. Los demás efectos adversos fueron la taquicardia, leucopenia, prolongación del QTc y náuseas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Introduction: Cyclophosphamide (CYC) is an alkylating agent used as an antineoplastic and immunosuppressant. In view of its toxicity and adverse safety profile, amid autoimmune diseases, it is reserved for remission induction in those with high disease activity or end organ damage. Objectives: To determine the adverse effects related to the intravenous infusion of CYC in patients of the Hospital Nacional de Itauguá between the years 2020 and 2021. Methods: A prospective, observational, descriptive study was carried out. Data was obtained from a survey filled by patients at the time of recruitment. Later, it was extrapolated to an Excel spreadsheet and analyzed using the statistical program EPI INFO 7. Results: The sample consisted of 70 patients, with a mean age of 38±15 years, 44 (63%) were women. 51 (73%) received CYC as immunosuppressive treatment in autoimmune diseases and 19 (27%) as antineoplastic treatment. The comorbidities detected were arterial hypertension in 37 patients (47%), diabetes mellitus in 1 patient (1%) and asthma in 2 patients (3%). 51 patients (73%) presented adverse effects. 82 adverse events were identified: hyponatremia in 25 (36%) patients, tachycardia in 19 (27%), nausea in 18 (26%), leukopenia in 15 (20%), and QTc prolongation in 5 (7%). Conclusion: Patients were predominantly women, with a mean age of 38 years. The most frequent adverse effect was hyponatremia, which was severe in 3 patients. Other adverse effects identified were tachycardia, leukopenia, QTc prolongation and nausea.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Ciclofosfamida]]></kwd>
<kwd lng="es"><![CDATA[efectos adversos]]></kwd>
<kwd lng="es"><![CDATA[efectos colaterales]]></kwd>
<kwd lng="es"><![CDATA[enfermedades autoinmunes]]></kwd>
<kwd lng="en"><![CDATA[Cyclophosphamide]]></kwd>
<kwd lng="en"><![CDATA[adverse effects]]></kwd>
<kwd lng="en"><![CDATA[side effects]]></kwd>
<kwd lng="en"><![CDATA[autoimmune diseases]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baltar]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ciclofosfamida en glomerulonefritis primarias y secundarias]]></article-title>
<source><![CDATA[Nefroplus]]></source>
<year>2010</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-15</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velasquez-Mendez]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Ramirez-Ruiz]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Vazquez-Duque]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramirez-Gomez]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de falla ovárica y factores de riesgo en pacientes con Lupus Eritematoso Sistémico tratadas con ciclofosfamida intravenosa]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2006</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>189-97</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batista]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Grass]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Avilés]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Portelles]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ciclofosfamida en el tratamiento de la esclerosis sistémica Cyclophosphamide in the Systemic Sclerosis Treatment.]]></article-title>
<source><![CDATA[Correo Cient Med]]></source>
<year>2015</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>706-17</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Simeón]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Plasín]]></surname>
<given-names><![CDATA[MÁ]]></given-names>
</name>
<name>
<surname><![CDATA[Xaubet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Fonollosa]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia de la ciclofosfamida endovenosa en el tratamiento de la enfermedad pulmonar intersticial asociada a la esclerosis sistémica]]></article-title>
<source><![CDATA[Arch Bronconeumol]]></source>
<year>2011</year>
<volume>47</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>239-45</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escobar-Torres]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identificación de los efectos Tóxicos producidos por los Fármacos Antineoplásicos utilizados en el Centro Radiooncologico del Caribe en la Ciudad de Cartagena, durante el 2010]]></article-title>
<source><![CDATA[Univ Nac Colomb Fac Med Dep Toxicol]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nuñez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Vasquez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pino J]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dosis única de ciclofosfamida disminuye la calidad espermática y el epitelio germinal masculino en ratones Unique cyclophosphamide doses in male mice decrease the spermatic quality and germinal epithelium]]></article-title>
<source><![CDATA[Revista Peruana de Biología]]></source>
<year>2012</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>193-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Gabarron]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Enriquez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sirvent]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Sepulcre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Millan I]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatotoxicidad tras tratamiento con ciclofosfamida en un paciente con vasculitis MPO-ANCA]]></article-title>
<source><![CDATA[Nefrologia]]></source>
<year>2011</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>496-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarro-Ulloaa]]></surname>
<given-names><![CDATA[OD]]></given-names>
</name>
<name>
<surname><![CDATA[Barranco-Camargo]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Jurado-López SP]]></surname>
<given-names><![CDATA[Z-CC]]></given-names>
</name>
<name>
<surname><![CDATA[G-P]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Muerte súbita debida a cardiotoxicidad aguda inducida por antraciclinas]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2018</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bellomio]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Berman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Spindler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lucero E]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ciclofosfamida ( CIC ) en lupus eritematoso sistémico (LES ): dosis acumulada y eventos adversos. Estudio multicéntrico]]></article-title>
<source><![CDATA[Rev Argent Reumatol]]></source>
<year>2010</year>
<volume>2</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>46-53</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendo-Alcolea]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cala-Calviño]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda-Leyva]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez- Escalante]]></surname>
<given-names><![CDATA[LTDN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reacciones adversas medicamentosas en pacientes con cancer atendidos en el hospital Oncologico Docente Conrado Benitez]]></article-title>
<source><![CDATA[Medisan]]></source>
<year>2017</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3145-51</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veronese]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hachul-Tessariol]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Scanavacca-Ibrahim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tan-Chen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sacilotto L]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of anthracycline, cyclophos- phamide and taxane chemotherapy on QTc measurements in patients with breast cancer]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2018</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dulery]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Razan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Labopin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sestili]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Malard]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early Cardiac Toxicity Associated With Post-Transplant Cyclophos- phamide in Allogeneic Stem Cell Transplantation]]></article-title>
<source><![CDATA[JACC Cardio- oncology]]></source>
<year>2021</year>
<volume>3</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>250-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonella]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Warley]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gutierrez]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Elizondo]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Angriman]]></surname>
<given-names><![CDATA[FOV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hiponatremia inducida por ciclofosfamida en altas dosis: estudio de cohorte retrospectiva]]></article-title>
<source><![CDATA[Rev Fac Cienc Med]]></source>
<year>2017</year>
<volume>74</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>201-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elazzazy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[EAGA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclophosphamide-induced symptomatic hyponatremia , a rare but severe side effect: a case report]]></article-title>
<source><![CDATA[Onco Targets Ther]]></source>
<year>2014</year>
<volume>2</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yuebo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chun]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhanguo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Symptomatic hyponatremia induced by low-dose cyclophosphamide in patient with systemic lupus erythematosus]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2020</year>
<volume>99</volume>
<numero>48</numero>
<issue>48</issue>
<page-range>22498</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Servioli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Facal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Consani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maciel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Citopenias hematológicas en enfermedades autoinmunes sistémicas]]></article-title>
<source><![CDATA[Archivos de Medicina Interna]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tashkin]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Clements]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Furst]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Strange]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Silver]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral cyclophosphamide (CYC) vs placebo for treatment of scleroderma related interstitial lung disease (SSc ILD) main findings from the scleroderma lung study]]></article-title>
<source><![CDATA[American Thoracic Society International]]></source>
<year>2006</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schuchter]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Hensley]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Meropol]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology, Chemotherapy, and Radiotherapy]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2002</year>
<volume>20</volume>
<page-range>2895-903</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shepherd]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Pringle]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Barnett]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Klingemann]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Reece]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1991</year>
<volume>9</volume>
<page-range>2016-20</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
